Holen Sie sich die Stockscreener-App
0.00
100.00%
-5.84
Handel nachbörslich:
5.84
5.84
+
Schlusskurs vom Vortag:
$5.84
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$221.21M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
0.00
EPS:
-2.57
Netto-Cashflow:
$-67.42M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$11.79
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
0.00 | 221.21M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Learn to Evaluate (NVRO) using the Charts - news.stocktradersdaily.com
Nevro Receives CE Mark for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy | Libero Quotidiano.it - Libero Quotidiano
Nevro (NYSE:NVRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Levi & Korsinsky, LLP Investigates Nevro Corp. Data Breach - ACCESS Newswire
Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN
Prudential Financial Inc. Grows Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach - ACCESS Newswire
Spinal Cord Stimulator Market to Set Phenomenal Growth From 2025 to 2034 | Medtronic,Boston Scientific,Nevro Corp - openPR.com
GMED Stock May Benefit Following the Acquisition of Nevro - MSN
Raymond James Financial Inc. Invests $287,000 in Nevro Corp. (NYSE:NVRO) - Defense World
Nevro (NYSE:NVRO) Coverage Initiated at StockNews.com - MarketBeat
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating - GlobeNewswire
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been Compromised - TradingView
(NVRO) Trading Report - news.stocktradersdaily.com
Nevro Files Notice of Data Breach Affecting Confidential Consumer Information - JD Supra
Globus acquires US medical device company Nevro - Yahoo Finance
Globus Medical Completes Acquisition of Nevro Corp. - MyChesCo
Nevro Corp. Investigated by Federman & Sherwood for Data Breach - GlobeNewswire
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series - MarketScreener
Nevro Data Breach Investigation - Claim Depot
Nevro Corp Completes Merger and Delists from NYSE - TipRanks
Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report? - Yahoo Finance
Nevro Corp completes merger with Globus Medical - Investing.com Australia
Nevro Corp. Data Breach Exposes SSNs & Health Information - Claim Depot
Globus Medical Closes Acquisition of Nevro - MarketScreener
Globus Medical Acquires Nevro Corp. - citybiz
Globus Medical completes acquisition of Nevro - MassDevice
Globus Medical completes acquisition of Nevro Corp. - grafa.com
Nevro Corp completes merger with Globus Medical By Investing.com - Investing.com South Africa
SEC Form POS AM filed by Nevro Corp. - Quantisnow
Globus Medical completes acquisition of Nevro Corp. - Benzinga
Major Medical Tech Merger: Globus Medical's $2.5B Market Push Through Nevro Acquisition - Stock Titan
StockNews.com Initiates Coverage on Nevro (NYSE:NVRO) - MarketBeat
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - MSN
Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Where are the Opportunities in (NVRO) - news.stocktradersdaily.com
Chronic Pain Associated with Painful Diabetic Neuropathy - openPR.com
SVP, Chief Operating Officer Christoforou Christofer was granted 852 shares and covered exercise/tax liability with 458 shares, increasing direct ownership by 0.32% to 123,588 units (SEC Form 4) - Quantisnow
SVP, Corp Dev and CLO Rashid Kashif was granted 1,136 shares and covered exercise/tax liability with 611 shares, increasing direct ownership by 0.38% to 140,462 units (SEC Form 4) - Quantisnow
SEC Form DEFA14A filed by Nevro Corp. - Quantisnow
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp.NVRO - Business Wire
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):